TY - JOUR
T1 - Towards achieving the end of the HIV epidemic
T2 - Advances, challenges and scaling-up strategies
AU - Balogun, Kayode
AU - Slev, Patricia R.
N1 - Publisher Copyright:
© 2022 The Canadian Society of Clinical Chemists
PY - 2023/7
Y1 - 2023/7
N2 - We are entering the 5th decade of the HIV epidemic and although there is no cure, critical advances have been made in treatment, prevention and diagnostics, transforming HIV into a survivable disease. Due to these advances, the UNAIDS has set a goal of “90–90–90” target by 2020, which has been extended now to 2030, to have 90% of individuals infected with HIV diagnosed, 90% of those diagnosed linked to care and 90% of people receiving ART and 90% of those receiving ART achieving an undetectable viral load. Today, the focus is on U = U, “undetectable equals untransmittable”, which takes advantage of improved diagnostics and treatment and preventive therapies that are combined with scale-up strategies. This article will review the advances in testing strategies and diagnostics, including rapid diagnostic tests and next generation sequencing, as well as the challenges that pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) now present for diagnosing and managing HIV infection.
AB - We are entering the 5th decade of the HIV epidemic and although there is no cure, critical advances have been made in treatment, prevention and diagnostics, transforming HIV into a survivable disease. Due to these advances, the UNAIDS has set a goal of “90–90–90” target by 2020, which has been extended now to 2030, to have 90% of individuals infected with HIV diagnosed, 90% of those diagnosed linked to care and 90% of people receiving ART and 90% of those receiving ART achieving an undetectable viral load. Today, the focus is on U = U, “undetectable equals untransmittable”, which takes advantage of improved diagnostics and treatment and preventive therapies that are combined with scale-up strategies. This article will review the advances in testing strategies and diagnostics, including rapid diagnostic tests and next generation sequencing, as well as the challenges that pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) now present for diagnosing and managing HIV infection.
KW - HIV PrEP
KW - HIV diagnostics
KW - HIV next generation sequencing
KW - HIV-2
KW - U=U
UR - http://www.scopus.com/inward/record.url?scp=85132797333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132797333&partnerID=8YFLogxK
U2 - 10.1016/j.clinbiochem.2022.05.006
DO - 10.1016/j.clinbiochem.2022.05.006
M3 - Article
C2 - 35640680
AN - SCOPUS:85132797333
SN - 0009-9120
VL - 117
SP - 53
EP - 59
JO - Clinical Biochemistry
JF - Clinical Biochemistry
ER -